The Russian Direct Investment Fund (RDIF), which has financed the development of the Sputnik V coronavirus vaccine, confirmed the figure to AFP without offering a breakdown of where the jab was distributed.
The human trial, announced in October before the recent rise in cases, is initially seeking up to 500 volunteers to be vaccinated at a hospital in the emirate of Abu Dhabi. Two doses of the vaccine will be given, 20 days apart, to volunteers, the statement said. Participants will have to be 18 years or older, have not previously been infected with COVID-19 or participated in other COVID-19 vaccine trials, it said.
Russia faced international criticism for approving a vaccine that hasn't completed advanced trials among tens of thousands of people, and experts both at home and abroad warned against its wider use until the studies are completed.
In September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.
The calculations were based on preliminary data obtained 42 days after the first dose, Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement.
The vaccine will be ready for wide distribution late this year or early next, officials say. That's roughly the same schedule as shots from rivals in the U.S., U.K. and China. Initial results from final-stage studies won’t be ready until November, with full data expected next year.
The US and other superpowers have laid claim to billions of Covid vaccine doses that are nearing the finish line. That’s sparked worries that poorer countries will be left behind and shots will be slow to reach many of them. Dozens of laboratories, researchers and companies from Thailand to Nigeria are bootstrapping their own work on inoculations.
Sputnik V has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology along with the Russian Direct Investment Fund (RDIF). The vaccine has not been tested in Phase 3 or larger clinical trials.
Russia has named its first approved coronavirus vaccine 'Sputnik V' for the foreign markets. It is a reference to the world's first satellite Sputnik and what Moscow sees as its success at becoming the first country to approve a vaccine, a top official said.Russia names its coronavirus vaccine as 'Sputnik V' in reference to world's first satellite
Russia has approved a coronavirus vaccine but the World Health Organisation is wary of it. "We are in close contact with Russian health authorities and discussions are ongoing with respect to possible WHO prequalification of the vaccine, but again prequalification of any vaccine includes the rigorous review and assessment of all required safety and efficacy data," WHO spokesman Tarik Jasarevic told.WHO in contact with russia on new coronavirus vaccine Sputnik V
RDIF has seen strong global interest in the vaccine and plans to conduct Phase 3 clinical trials in different countries, including Saudi Arabia, UAE, Brazil, India and Philippines, and start mass production in other countries in partnership with local sovereign wealth funds, including India, South Korea and Brazil, as well as, in Saudi Arabia, Turkey and Cuba, according to the statement.
Russia has developed the first vaccine offering "sustainable immunity" against the coronavirus, President Vladimir Putin announced Tuesday. "This morning, for the first time in the world, a vaccine against the new coronavirus was registered" in Russia, he said during a televised video conference call with government ministers. "One of my daughters had this vaccine. I think in this sense she took part in the experiment," Putin said.Russia announces World's 'first' Covid-19 vaccine, Putin says daughter inoculated
"The vaccine developed by the Gamaleya centre will be registered on August 12. At the moment, the last, third, stage is underway. The trials are extremely important. We have to understand that the vaccine must be safe. Medical professionals and senior citizens will be the first to get vaccinated," Gridnev told reporters at the opening of a cancer centre building in the city of Ufa.
Putin said Moscow was ready to cooperate with all other countries on coronavirus vaccines, but urged against politicising the process, the day after vaccine developers Pfizer Inc and BioNTech said their experimental COVID-19 vaccine was more than 90% effective.
Last week, Russia became the first country in the world to license a coronavirus vaccine when President Vladimir Putin announced its approval. But the vaccine has not yet passed the advanced trials normally required to prove it works before being licensed, a major breach of scientific protocol.
Lauding Russia for the vaccine, Raut, in his weekly column 'Rokhtokh' in the Shiv Sena mouthpiece 'Saamana', said this was a sign of being a superpower, and added that Indian politicians will not follow Russia's example as a model since "they are in love with America".
The country is pushing ahead with several vaccine prototypes and one trialled by the Gamaleya institute in Moscow has reached advanced stages of development and is about to pass state registration, officials said. "We are very much counting on starting mass production in September," Industry Minister Denis Manturov said.
While the country hopes to start mass-producing the vaccine by October and plans to offer the first doses to essential workers, many in the science community seem unimpressed. The announcement should be taken "with a pinch of salt", said Indian immunologist Vineeta Bal.